Cantor Fitzgerald Estimates Humacyte FY2025 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Humacyte in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($0.95) per share for the year. The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.

A number of other research firms also recently issued reports on HUMA. Benchmark lifted their price target on shares of Humacyte from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, December 23rd. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Tuesday. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. BTIG Research reaffirmed a "buy" rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. Finally, HC Wainwright reissued a "buy" rating and set a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of "Buy" and an average price target of $13.71.

Humacyte Stock Performance

Shares of NASDAQ HUMA remained flat at $4.59 during midday trading on Thursday. The company had a trading volume of 1,748,895 shares, compared to its average volume of 2,956,959. The company has a market capitalization of $577.70 million, a PE ratio of -3.43 and a beta of 1.32. Humacyte has a 52-week low of $2.80 and a 52-week high of $9.97. The company's 50-day moving average is $4.52 and its two-hundred day moving average is $5.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.08). During the same quarter in the prior year, the firm earned ($0.25) EPS.

Insider Buying and Selling at Humacyte

In other news, CEO Laura E. Niklason sold 811,172 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the transaction, the chief executive officer now directly owns 2,419,712 shares of the company's stock, valued at $10,743,521.28. The trade was a 25.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. 11.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Humacyte

Several large investors have recently made changes to their positions in HUMA. State Street Corp grew its holdings in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock valued at $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company's stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period. Renaissance Technologies LLC lifted its stake in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company's stock valued at $2,881,000 after purchasing an additional 524,600 shares during the last quarter. Marshall Wace LLP increased its position in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company's stock worth $2,226,000 after buying an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new stake in Humacyte in the second quarter valued at approximately $1,550,000. Institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.